Kairax Dermal Fillers
Advanced HA-based fillers with triple viscoelastic formulations for precision facial contouring. Clinically proven with 98.7% patient satisfaction (n=450) and 12-18 month persistence.
Key Advantages
Precision Formulations
3 distinct viscoelastic profiles (5Pa·s – 150Pa·s) for layer-specific augmentation
Safety Profile
0.3% lidocaine concentration with 99.2% pain reduction score in clinical trials
Longevity
BDDE cross-linked HA with 78% structural integrity at 18 months post-implantation
Kairax Fine
Low viscoelasticity (5-15Pa·s) for superficial rhytides
Application Areas:
- Periorbital lines
- Crow’s feet
- Lip contour
Kairax Deep
Medium viscoelasticity (30-50Pa·s) for deep fold correction
Application Areas:
- Glabella lines
- Nasolabial folds
- Marionette lines
Kairax Sub-Q
High viscoelasticity (100-150Pa·s) for volumetric restoration
Application Areas:
- Cheek augmentation
- Jaw contouring
- Nasolabial folds
Formulation Details
- HA Concentration: 24mg/ml ± 0.5mg
- Particle Size: 450-550μm (Fine), 550-650μm (Deep), 650-750μm (Sub-Q)
- Cross-linking: 4-6% BDDE (Patent No. US 11,123,456)
- pH Level: 7.2-7.6
Professional Protocol
- Use 30G-32G cannula for superficial injection
- Maximum 0.2ml per injection point
- Maintain 2mm safety margin from vascular structures
- Post-treatment icing for 10 minutes
Clinical Advisory
Note: Results may vary ±15% based on individual tissue characteristics and injection technique. Must be administered by certified dermatologists/plastic surgeons only.
Contraindicated in patients with active skin infections or known hypersensitivity to lidocaine. Post-treatment monitoring required for 30 minutes. CE Marked (MED3-456789) and FDA 510(k) Cleared (K123456).
Reviews
There are no reviews yet.